Donor Site Morbidity of the Medial Sural Artery Perforator (MSAP) Free Flap for Head & Neck Reconstruction

作者：Lillian W. Dattilo, Emilie C. M. de Groot, Sarah C. Nyirjesy, Omar A. Karadaghy, Elizabeth Noyes, Matthew E. Spector, Jeremy D. Richmon, Derrick T. Lin, Mark A. Varvares, Allen L. Feng · 发表于：Head & Neck · 年份：2025 · DOI：10.1002/hed.28187 · 被引用次数：4 · 研究领域：Reconstructive Surgery and Microvascular Techniques、Tracheal and airway disorders、Cleft Lip and Palate Research

BACKGROUND: Minimal donor site morbidity is often cited as one of the main advantages of the medial sural artery perforator (MSAP) free flap; however, few studies have examined functional outcomes. METHODS: This retrospective cohort study analyzed patients undergoing MSAP for head and neck reconstruction from 2022 to 2024. A modified lower extremity functional scale (LEFS), with 80 being a maximum score, was administered to assess functional morbidity. RESULTS: Twenty two patients underwent successful MSAP flap. At < 1 month after surgery, the average LEFS was 56.0 (95% CI, 43.8-68.2). At 1-3 months, the average score was 63.0 (95% CI, 56.0-70.0); at 3-6 months, it was 75.0 (95% CI, 70.0-80.0), and at 6-12 months, it was 78.1 (95% CI, 75.4-80.0). Beyond 12 months, the average score was 79.8 (95% CI, 79.8-80.0). CONCLUSIONS AND RELEVANCE: The MSAP free flap is an excellent free tissue option for head & neck reconstruction with minimal donor site morbidity.